Abstract
To examine disease activity and physical function after implementation of treat-to-target (T2T) strategy in patients with established rheumatoid arthritis (RA) over a long-term period. Patients with RA were started on a T2T strategy in 2005 and followed through 2014. Patients were seen every 3–4 months until remission/low disease activity was achieved and every 6 months thereafter. Disease activity was measured by the DAS28 and CDAI, and physical function by the HAQ-DI. Results were presented as all observed data, without imputation for missing values. Changes in disease activity and physical function were evaluated by generalized estimating equations (GEE). Two hundred and twenty-nine patients were included, with a mean (SD) disease duration of 10.6 (7.4) years. Significant improvements were seen in both composite scores during the follow-up period, as demonstrated by DAS28 (β coefficient = 0.19; 95% CI = 0.16–0.21; p < 0.01) and by CDAI (β coefficient = 1.59; 95% CI = 1.84–1.34; p < 0.01). Physical function also improved, as demonstrated by HAQ-DI (β coefficient = 0.03; 95% CI = 0.02–0.04; p < 0.01). Biological therapy was associated with improvement in disease activity and in physical function. Leflunomide was only associated with improvement in physical function. Clinically meaningful reductions of DAS28, CDAI and HAQ-DI were observed in patients with established rheumatoid arthritis from 2005 to 2014. Implementation of new therapeutic options, in the scenario of T2T strategy, was associated with improvement in disease activity and physical function.
This is a preview of subscription content, log in via an institution to check access.
References
Horton SC, Walsh C a E, Emery P (2011) Established rheumatoid arthritis: Rationale for best practice—physicians’ perspective of how to realise tight control in clinical practice. Best Pract Res Clin Rheumatol 25:509–521
Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–269
Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15
Symmons D, Tricker K, Roberts C, Davies L, Dawes P, Scott DL (2005) The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. Health Technol Assess 9:1–78
Fransen J, Moens HB, Speyer I, van Riel PLCM (2005) Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 64:1294–1298
Gullick NJ, Oakley SP, Zain A, Gibson T, Jones T, Mistlin A et al (2012) Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years. Rheumatology 51:759–761
Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS (2013) Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis Care Res 65:1401–1409
Santos-Moreno PI, de la Hoz-Valle J, Villarreal L, Palomino A, Sánchez G, Castro C (2015) Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. Clin Rheumatol 34:215–220
Brenol CV, da Chakr RMS, Andrade NPB, Toni M, Laurindo IMM, Brenol JCT et al (2015) Daily practice feasibility and effectiveness of treating long-standing rheumatoid arthritis to target with synthetic disease-modifying antirheumatic drugs: a prospective cohort study. Clin Rheumatol 34:1781–1785
Bértolo MB, Brenol CV, Schainberg CG, Neubarth F (2007) Update on the Brazilian consensus for the diagnosis and treatment of rheumatoid arthritis. Rev Bras Reumatol 47(3):151–159
Mota LMH Da, Cruz BA, Brenol CV, Pereira IA, Rezende-Fronza LS, Bertolo MB et al (2012) Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide. Rev Bras Reumatol 52:152–174
González-Alvaro I, Descalzo MA, Carmona L (2008) Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort. Arthritis Res Ther 10(6):R138
Martínez MS, García-Monforte A, Rivera J (2001) Survival study of rheumatoid arthritis patients in Madrid (Spain). A 9-year prospective follow-up. Scand J Rheumatol 30:195–198
van Tuyl LHD, Boers M, Lems WF, Landewe RB, Han H, van der Linden S et al (2010) Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 69:807–812
Markusse IM, Dirven L, Han KH, Ronday HK, Kerstens PJSM, Lems WF et al (2015) Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: why keep patients doing their best? Arthritis Care Res 67:739–745
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors have declared no conflicts of interest.
This work has been approved by HCPA ethics committee and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
All participants gave their informed consent prior to their inclusion in the study.
Rights and permissions
About this article
Cite this article
de Andrade, N.P.B., da Silva Chakr, R.M., Xavier, R.M. et al. Long-term outcomes of treat-to-target strategy in established rheumatoid arthritis: a daily practice prospective cohort study. Rheumatol Int 37, 993–997 (2017). https://doi.org/10.1007/s00296-017-3695-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-017-3695-4